Obigen Pharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	87.37	148.86	204.54	427.41
Short-Term Investments	427	608.7	739.3	-
Cash & Short-Term Investments	514.37	757.56	943.84	427.41
Cash Growth	-32.10%	-19.74%	120.83%	-
Other Receivables	84.98	76.62	1.23	0.03
Receivables	84.98	76.62	1.23	0.03
Other Current Assets	37.94	3.68	71.48	63.73
Total Current Assets	637.29	837.87	1,017	491.17
Property, Plant & Equipment	206.1	274.37	312.79	303.34
Other Intangible Assets	626.76	668.82	707.2	748.43
Other Long-Term Assets	13.99	13.12	16.18	8.68
Total Assets	1,484	1,794	2,053	1,552
Accrued Expenses	15.73	17.34	7.11	3.55
Current Portion of Leases	15.09	14.8	13.77	6.73
Other Current Liabilities	4.02	5.23	3.17	6.78
Total Current Liabilities	34.83	37.37	24.05	17.06
Long-Term Leases	66.08	81.16	95.96	49.69
Other Long-Term Liabilities	0.55	0.55	0.56	0
Total Liabilities	101.46	119.08	120.57	66.75
Common Stock	1,069	1,060	1,060	760.03
Additional Paid-In Capital	1,511	1,488	1,470	770.43
Retained Earnings	-1,199	-872.71	-598.41	-353.11
Comprehensive Income & Other	1.3	0.24	0.24	307.53
Shareholders' Equity	1,383	1,675	1,932	1,485
Total Liabilities & Equity	1,484	1,794	2,053	1,552
Total Debt	81.16	95.96	109.73	56.42
Net Cash (Debt)	433.21	661.6	834.11	370.99
Net Cash Growth	-34.52%	-20.68%	124.83%	-
Net Cash Per Share	4.08	6.24	8.14	4.88
Filing Date Shares Outstanding	106.92	106	106	76
Total Common Shares Outstanding	106.92	106	106	76
Working Capital	602.46	800.5	992.5	474.11
Book Value Per Share	12.92	15.80	18.23	19.54
Tangible Book Value	755.92	1,006	1,225	736.44
Tangible Book Value Per Share	7.06	9.49	11.56	9.69
Machinery	145.86	194.95	163.01	160.2
Construction In Progress	-	-	9.72	26.76
Leasehold Improvements	165.26	177.77	168.51	138.8

Source: S&P Capital IQ. Standard template. Financial Sources.